Table 4

Data taken from clinical and electronic records of those recruited to the MaCROS study

Patient noAgeProbiotic/ placeboDiagnosisInpatient (routine chemotherapy)Was routine admission for chemotherapy extended?FebrileFebrile neutropenic?Positive blood culture?Organism
1*12 yearsProbioticEwing’s sarcomaYesNoNoNoN/A
213 yearsPlaceboOsteosarcomaYesYesYesNoNo
37 yearsProbioticUndifferentiated sarcomaYesNoNoNoNA
412 yearsPlaceboHR NBL-
HD chemo and stem cell rescue
51 year, 7 monthsProbioticHR NBLYesNoNoNoYes Streptococcus mitis/oralis, Streptococcus vestibularis,
Streptococcus parasangui
61 year, 7 monthsProbioticHR NBL
HD chemo and stem cell rescue
YesNA†YesNoYesGram negative bacilli
714 yearsPlaceboAMLYesNA†YesYesNo
83 yearsPlaceboNHLYesYesYesYesNo
9*15 yearsPlaceboMetastatic-relapsed osteosarcomaNoNoNoNoNA
108 yearsPlaceboOsteosarcomaYesYesYesNoNo
  • *Withdrawn.

  • †Inpatient until count recovered.

  • AML, acute myeloid leukaemia; HD, high dose; HR NBL, high-risk neuroblastoma; NHL, non-Hodgkins lymphoma.